Abstract
Background
Acute liver failure is idiopathic and drug-related in, respectively, around 50 and 15 % of children. Population-based, epidemiologic data about the pattern of disease manifestation and incidence of less severe acute liver injury, either idiopathic or potentially drug-attributed are limited in children and adolescents.
Objectives
(i) To assess the incidence of idiopathic acute liver injury (ALI) and its clinical features in children and adolescent outpatients; and (ii) to investigate the role of the drug as a potential cause of ALI which is considered idiopathic.
Methods
A retrospective cohort study was performed during the years 2000–2008. Data were retrieved from three longitudinal electronic healthcare databases in two European countries: Pedianet and Health Search/CSD Longitudinal Patient Database from Italy and the Integrated Primary Care Information database from The Netherlands. Cases of idiopathic acute liver injury in population aged <18 years were identified by exclusion of all competing causes of liver injury (e.g. viral, autoimmune hepatitis), according to CIOMS criteria. The potential role of drug exposure as actual underlying cause of idiopathic ALI was detected through signal detection mining techniques. Both pooled and country-specific incidence rates [IR/100,000 person-years (PYs)] of idiopathic ALI and pooled adjusted rate ratios (RR) of drugs identified as a potential cause of idiopathic ALI, plus 95 % confidence intervals (CI) were estimated using the custom-built software Jerboa.
Results
Among 785 definite cases of idiopathic ALI, the pooled IR was 62.4/100,000 PYs (95 % CI 58.1–66.8). The country-specific IR was higher in Italy (73.0/100,000 PYs, 95 % CI 67.8–78.4) than in The Netherlands (21.0/100,000 PYs, 95 % CI 16.0–27.2) and increased with age in both countries. Isolated elevations of liver enzymes were reported in around two-thirds of cases in Italy, while in The Netherlands the cases were more often identified by a combination of signs/symptoms. Among drugs detected as potential underlying cause of idiopathic ALI, clarithromycin (RR 25.9, 95 % CI 13.4–50), amoxicillin/clavulanic acid (RR 18.6, 95 % CI 11.3–30.6), and amoxicillin (RR 7.5, 95 % CI 3.4–16.8) were associated with the highest risk compared to non-use.
Conclusion
The incidence of idiopathic ALI in paediatrics is relatively low and comparable with adults. Clinical presentations differ between the two European countries. Signal detection in healthcare databases allowed identifying antibiotics as the drugs mostly associated with ALI with apparently unknown aetiology.
Similar content being viewed by others
References
Narkewicz MR, Dell Olio D, Karpen SJ, et al. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr. 2009;155:801–6.e1.
Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (Baltimore). 2010;52:730–42.
De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24:1187–95.
Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–21.
Molleston JP, Fontana RJ, Lopez MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53:182–9.
Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18:1176–84.
Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–93.
Cricelli C, Mazzaglia G, Samani F, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med. 2003;25:254–7.
Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093–100.
Neubert A, Verhamme K, Murray ML, et al. The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and The Netherlands. Pharmacol Res. 2010;62:243–8.
Sen EF, Verhamme KM, Neubert A, et al. Assessment of pediatric asthma drug use in three European countries; a TEDDY study. Eur J Pediatr. 2011;170:81–92.
Sturkenboom MC, Verhamme KM, Nicolosi A, et al. Drug use in children: cohort study in three European countries. BMJ (Clin Res Edn.) 2008;337:a2245.
van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011;60(12):1650–9.
Charlton M, Angulo P, Chalasani N, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (Baltimore). 2008;47:484–92.
Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol. 1990;28:317–22.
Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272–6.
de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case–control study. Br J Clin Pharmacol. 2004;58:71–80.
Duh MS, Walker AM, Kronlund KH Jr. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf. 1999;8:275–83.
Lucena MI, Garcia-Cortes M, Cueto R, et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008;22:141–58.
Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ (Clin Res Edn). 2003;327:18–22.
Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (Baltimore). 2011;54:931–9.
Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731–9.
Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20:1–11.
Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf. 2011;20:292–9.
Trifiro G, Patadia V, Schuemie MJ, et al. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform. 2011;166:25–30.
Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009;29:337–47.
Hussaini SH, O’Brien CS, Despott EJ, et al. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol. 2007;19:15–20.
Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–54.
Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (Baltimore) 2002;36:451–5.
Nicastro E, Ranucci G, Vajro P, et al. Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatology (Baltimore) 2010;52:1948–56.
Ferrajolo C, Capuano A, Verhamme KM, et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol. 2010;70:721–8.
Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118:250–67.
Murray KF, Hadzic N, Wirth S, et al. Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr. 2008;47:395–405.
Pineiro-Carrero VM, Pineiro EO. Liver. Pediatrics. 2004;113:1097–106.
Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996;156:1327–32.
Salvo F, Polimeni G, Moretti U, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother. 2007;60:121–6.
Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338–47.
Cuzzolin L, Antonucci R, Fanos V. Paracetamol (Acetaminophen) Efficacy and Safety in the Newborn. Curr Drug Metabol. 2012;14(2):178–85.
Observational Medical Outcomes Partnership (OMOP). Available from URL:http://omop.fnih.org. Accessed 23 Feb 2011.
Chan DF, Li AM, Chu WC, et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord. 2004;28:1257–63.
Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical–pathological study and effect of lifestyle advice. Hepatology (Baltimore). 2006;44:458–65.
Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2000;30:48–53.
Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology (Baltimore). 2005;42:641–9.
Acknowledgments
We would like to thank Prof. John Van den Anker and Dr. Giuseppe Indolfi for their revision of the final version of the manuscript, and the Erasmus Trustfonds for research supporting.
Financial disclosure
Nothing to disclose.
Conflict of interest
Katia MC Verhamme has been involved as project leader in analyses contracted by various pharmaceutical companies and received unconditional research grants from Pfizer, Yamanouchi, and Boehringer Ingelheim, none of which are related to the subject of this study. Vera E Valkhoff has conducted research for AstraZeneca as an employee of the Erasmus Medical Center. Miriam CJM Sturkenboom is scientific coordinator of the IPCI group which is partially funded through unconditional research grants from the pharmaceutical industry, namely Pfizer, Merck, AstraZeneca, Eli Lilly, GSK and Altana. She has been consultant to Pfizer, Novartis Consumer Health, Servier, Celgene and Lundbeck. Carmen Ferrajolo, Gianluca Trifiró, Geert W ‘t Jong, Carlo Giaquinto, Gino Picelli, Alessandro Oteri, Sandra de Bie, Martijn J Schuemie, Giampiero Mazzaglia, Claudio Cricelli, Francesco Rossi, and Annalisa Capuano declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ferrajolo, C., Verhamme, K.M.C., Trifirò, G. et al. Idiopathic Acute Liver Injury in Paediatric Outpatients: Incidence and Signal Detection in Two European Countries. Drug Saf 36, 1007–1016 (2013). https://doi.org/10.1007/s40264-013-0045-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-013-0045-7